A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
Clinical trial NCT05529316 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05529316
- Sponsor
- Agenus Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-12
- Primary completion
- 2028-02-01
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.